Troy Wichterman Sells 990 Shares of BioLife Solutions (NASDAQ:BLFS) Stock

BioLife Solutions, Inc. (NASDAQ:BLFS) CFO Troy Wichterman sold 990 shares of the firm’s stock in a transaction dated Tuesday, January 6th. The stock was sold at an average price of $25.59, for a total value of $25,334.10. Following the transaction, the chief financial officer owned 150,746 shares in the company, valued at approximately $3,857,590.14. This trade represents a 0.65% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Troy Wichterman also recently made the following trade(s):

• On Tuesday, December 9th, Troy Wichterman sold 1,033 shares of BioLife Solutions stock. The shares were sold at an average price of $25.13, for a total transaction of $25,959.29.
• On Thursday, December 4th, Troy Wichterman sold 30,000 shares of BioLife Solutions stock. The shares were sold at an average price of $25.72, for a total transaction of $771,600.00.
• On Tuesday, November 25th, Troy Wichterman sold 584 shares of BioLife Solutions stock. The shares were sold at an average price of $26.74, for a total transaction of $15,616.16.

BioLife Solutions Stock Performance

BLFS opened at $24.86 on Friday. The firm’s fifty day moving average is $25.41 and its two-hundred day moving average is $24.83. The firm has a market cap of $1.20 billion, a PE ratio of -355.09 and a beta of 1.93. BioLife Solutions, Inc. has a twelve month low of $19.10 and a twelve month high of $29.62.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on BLFS. Wall Street Zen cut BioLife Solutions from a “buy” rating to a “hold” rating in a report on Sunday, November 30th. Northland Securities set a $34.00 target price on shares of BioLife Solutions in a report on Monday. Weiss Ratings reiterated a “sell (d-)” rating on shares of BioLife Solutions in a report on Wednesday, October 8th. UBS Group reissued a “buy” rating on shares of BioLife Solutions in a research report on Monday, December 29th. Finally, Zacks Research lowered shares of BioLife Solutions from a “strong-buy” rating to a “hold” rating in a report on Monday, December 8th. Three investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $32.00.

BioLife Solutions News Roundup

Here are the key news stories impacting BioLife Solutions this week:

• Positive Sentiment: Analyst support that could limit downside — Northland has a $34 target and UBS maintains a buy rating; MarketBeat shows a consensus “Hold” with an average price target near $32, which provides a possible upside reference for investors. MarketBeat BLFS Analyst Coverage
• Neutral Sentiment: Company announced the planned retirement of a key quality & operations executive (effective date/details in the filing). A planned/announced retirement can be orderly but raises succession and continuity questions for manufacturing/quality functions. BioLife announces planned retirement
• Neutral Sentiment: Analysts are issuing Q1 earnings forecasts for BLFS; investors should watch upcoming guidance/quarterly results for confirmation of demand trends in cryopreservation and cell/gene therapy supply chains. Analysts Issue Forecasts for BLFS Q1 Earnings
• Negative Sentiment: Multiple insider sales reported on the same filing period — EVP Aby Mathew sold 405 shares, CMO Todd Berard sold 344 shares, CFO Troy Wichterman sold 990 shares, plus additional smaller officer/insider sales (Sarah Aebersold, Karen Foster). All sales were executed around Jan 6 at ~ $25.59; while sizes are small relative to holdings, clustered executive selling can spook investors. Insider selling report

Institutional Trading of BioLife Solutions

A number of hedge funds and other institutional investors have recently made changes to their positions in BLFS. State of Wyoming boosted its holdings in BioLife Solutions by 353.1% during the first quarter. State of Wyoming now owns 1,912 shares of the medical equipment provider’s stock worth $44,000 after purchasing an additional 1,490 shares during the last quarter. Hantz Financial Services Inc. increased its stake in BioLife Solutions by 54.1% in the 3rd quarter. Hantz Financial Services Inc. now owns 1,877 shares of the medical equipment provider’s stock valued at $48,000 after buying an additional 659 shares during the last quarter. Quarry LP lifted its position in BioLife Solutions by 50.9% during the 3rd quarter. Quarry LP now owns 2,113 shares of the medical equipment provider’s stock worth $54,000 after buying an additional 713 shares in the last quarter. Ameritas Investment Partners Inc. boosted its stake in shares of BioLife Solutions by 12.8% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,873 shares of the medical equipment provider’s stock worth $83,000 after buying an additional 441 shares during the last quarter. Finally, PNC Financial Services Group Inc. boosted its stake in shares of BioLife Solutions by 82.0% during the 3rd quarter. PNC Financial Services Group Inc. now owns 4,425 shares of the medical equipment provider’s stock worth $113,000 after buying an additional 1,994 shares during the last quarter. 93.24% of the stock is currently owned by institutional investors and hedge funds.

About BioLife Solutions

BioLife Solutions (NASDAQ:BLFS) specializes in biopreservation and cold chain workflow solutions for cell and gene therapies, regenerative medicine and other advanced biologics. The company develops and markets proprietary cryopreservation media and technology platforms designed to maintain cell viability and functionality during processing, storage and transport. BioLife’s product portfolio addresses critical steps in the manufacturing and distribution of cell-based products, helping life science researchers and biopharmaceutical manufacturers protect and preserve living cells.

The company’s flagship offerings include CryoStor, a family of serum-free cryopreservation media; HypoThermosol, a hypothermic storage solution for short-term cell and tissue preservation; and the ThawSTAR system, an automated cell thawing instrument that delivers controlled and reproducible warming of frozen cell therapies.